These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 4007294)
1. Increase in serum total cholesterol and low-density lipoprotein cholesterol by high-dose chenodeoxycholic acid in patients with radiolucent gallstones significantly reversed during preventive low dose after gallstone dissolution. Pérez-Aguilar F; Bretó M; Alegre B; Berenguer J Digestion; 1985; 31(4):225-33. PubMed ID: 4007294 [TBL] [Abstract][Full Text] [Related]
2. Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones. Leiss O; von Bergmann K Scand J Gastroenterol; 1982 Aug; 17(5):587-92. PubMed ID: 7178821 [TBL] [Abstract][Full Text] [Related]
3. Outcome of chenodeoxycholic acid (CDCA) treatment in 125 patients with radiolucent gallstones. Factors influencing efficacy, withdrawal, symptoms and side effects and post-dissolution recurrence. Maton PN; Iser JH; Reuben A; Saxton HM; Murphy GM; Dowling RH Medicine (Baltimore); 1982 Mar; 61(2):86-97. PubMed ID: 7062856 [TBL] [Abstract][Full Text] [Related]
4. National Cooperative Gallstone Study: the effect of chenodeoxycholic acid on lipoproteins and apolipoproteins. Albers JJ; Grundy SM; Cleary PA; Small DM; Lachin JM; Schoenfield LJ Gastroenterology; 1982 Apr; 82(4):638-46. PubMed ID: 6800869 [TBL] [Abstract][Full Text] [Related]
5. Comparison of fixed doses of chenodeoxycholic acid for gallstone dissolution. Bateson MC; Ross PE; Murison J; Bouchier IA Lancet; 1978 May; 1(8074):1111-4. PubMed ID: 77412 [TBL] [Abstract][Full Text] [Related]
6. Chenodeoxycholic acid treatment of gallstones. A follow-up report and analysis of factors influencing response to therapy. Iser JH; Dowling H; Mok HY; Bell GD N Engl J Med; 1975 Aug; 293(8):378-83. PubMed ID: 1152936 [TBL] [Abstract][Full Text] [Related]
7. Effect of obesity and weight reduction on biliary cholesterol saturation and the response to chenodeoxycholic acid. Reuben A; Qureshi Y; Murphy GM; Dowling RH Eur J Clin Invest; 1986 Apr; 16(2):133-42. PubMed ID: 3089808 [TBL] [Abstract][Full Text] [Related]
8. The effects of chenodiol on biliary lipids and their association with gallstone dissolution in the National Cooperative Gallstone Study (NCGS). Grundy SM; Lan SP; Lachin J J Clin Invest; 1984 Apr; 73(4):1156-66. PubMed ID: 6368591 [TBL] [Abstract][Full Text] [Related]
9. Treatment of radiolucent gallstones with CDCA or UDCA. A multicenter trial. Polli EE; Bianchi PA; Conte D; Sironi L Digestion; 1981; 22(4):185-91. PubMed ID: 7030835 [TBL] [Abstract][Full Text] [Related]
10. Franco-Belgian cooperative study of ursodeoxycholic acid in the medical dissolution of gallstones: a double-blind, randomized, dose-response study, and comparison with chenodeoxycholic acid. Erlinger S; Le Go A; Husson JM; Fevery J Hepatology; 1984; 4(2):308-14. PubMed ID: 6706305 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of bile acid therapy for gallstone dissolution: a meta-analysis of randomized trials. May GR; Sutherland LR; Shaffer EA Aliment Pharmacol Ther; 1993 Apr; 7(2):139-48. PubMed ID: 8485266 [TBL] [Abstract][Full Text] [Related]
13. Speed of change in biliary lipids and bile acids with chenodeoxycholic acid--is intermittent therapy feasible? Iser JH; Murphy GM; Dowling RH Gut; 1977 Jan; 18(1):7-15. PubMed ID: 838406 [TBL] [Abstract][Full Text] [Related]
14. [Changes in the pattern of serum biliary acids and lipoprotein picture during therapy with biliary acids in cholesterol lithiasis]. Di Mario F; Angonese C; Del Favero G; Aggio L; Meggiato T; Scalon P; Basso D; Plebani M; Burlina A; Naccarato R G Clin Med; 1990; 71(6-7):435-41. PubMed ID: 2258026 [TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of 'Cheno' and 'Urso' in the medical treatment of gallstones. Meredith TJ; Williams GV; Maton PN; Murphy GM; Saxton HM; Dowling RH Gut; 1982 May; 23(5):382-9. PubMed ID: 7076015 [TBL] [Abstract][Full Text] [Related]
16. The medical treatment of cholesterol gallstones: experience with chenodeoxycholic acid. Barbara L; Roda E; Roda A; Sama C; Festi D; Mazzella G; Aldini R Digestion; 1976; 14(3):209-19. PubMed ID: 955328 [TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: a comparative randomized study. Roda E; Bazzoli F; Labate AM; Mazzella G; Roda A; Sama C; Festi D; Aldini R; Taroni F; Barbara L Hepatology; 1982; 2(6):804-10. PubMed ID: 7141392 [TBL] [Abstract][Full Text] [Related]
18. Resistance to chenodeoxycholic acid (CDCA) treatment in obese patients with gall stones. Iser JH; Maton PN; Murphy GM; Dowling RH Br Med J; 1978 Jun; 1(6126):1509-12. PubMed ID: 656777 [TBL] [Abstract][Full Text] [Related]
20. Lack of response to chenodeoxycholic acid in obese and non-obese patients. Role of cholesterol synthesis and possible response to ursodeoxycholic acid. Maton PN; Murphy GM; Dowling RH Gut; 1980 Dec; 21(12):1082-6. PubMed ID: 7461467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]